Cemiplimab in patients with advanced cutaneous squamous cell carcinoma: longer follow-up
Cemiplimab ( Libtayo ) monotherapy achieves clinically meaningful activity in patients with advanced cutaneous squamous cell carcinoma ( CSCC ) ( metastatic [ mCSCC ] or locally advanced [ laCSCC ] not amenable to curative surgery or curative radiation ) and has a safety profile consistent with other anti-PD-1 agents.
Based on initial data ( median follow-up of 9.4 months in the pivotal study ), Cemiplimab was approved for the treatment of patients with advanced CSCC.
Historical data shows median overall survival ( OS ) of approximately 15 months with conventional chemotherapy or EGFR inhibitors ( ASCO 2019, e21033 ).
Researchers have presented approximately 1-year additional follow-up from the largest prospective data set in advanced CSCC.
Patients received Cemiplimab 3 mg/kg Q2W ( Group [Gp] 1; mCSCC; Gp 2, laCSCC ) or Cemiplimab 350 mg Q3W ( Gp 3, mCSCC ).
The primary endpoint was objective response rate ( ORR; complete response + partial response ) per independent central review ( ICR ).
Data are presented per investigator review ( INV ).
193 patients were enrolled ( Gp 1, n = 59; Gp 2, n = 78; Gp 3, n = 56 ). 128 patients had received no prior anti-cancer systemic therapy, 65 patients were previously treated.
As of Oct 11, 2019 ( data cut-off ), median duration of follow-up was 15.7 months ( range: 0.6–36.1 ) among all patients; 18.5 months ( range: 1.1–36.1 ) for Gp 1, 15.5 months ( range: 0.8–35.0 ) for Gp 2, and 17.3 months ( range: 0.6–26.3 ) for Gp 3.
ORR per investigator review was 54.4% ( 95% CI: 47.1–61.6 ) for all patients; 50.8% ( 95% CI: 37.5–64.1 ) for Gp 1, 56.4% ( 95% CI: 44.7–67.6 ) for Gp 2, and 55.4% ( 95% CI: 41.5–68.7 ) for Gp 3.
ORR per investigator review was 57.8% ( 95% CI: 48.8–66.5 ) among treatment-naïve patients and 47.7% ( 95% CI: 35.1–60.5 ) among previously treated patients.
Median duration of response ( DOR ) has not been reached ( observed DOR range: 1.8–34.2 months ).
In responding patients, estimated proportion of patients with ongoing response at 24 months was 76.0% ( 95% CI: 64.1–84.4 ).
Median overall survival has not been reached. Estimated OS at 24 months was 73.3% ( 95% CI: 66.1–79.2 ).
The most common treatment-emergent adverse events ( TEAEs ) by any grade were fatigue ( 34.7% ), diarrhea ( 27.5% ), and nausea ( 23.8% ).
The most common grade 3 TEAEs or more were hypertension ( 4.7% ) and anemia and cellulitis ( each 4.1% ).
In conclusion, for patients with advanced cutaneous squamous cell carcinoma, Cemiplimab achieves ORRs, DOR and survival superior to what has been reported with other agents. ( Xagena )
Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020
Resected stage III melanoma with BRAF mutations: 5-year follow-up of adjuvant Dabrafenib plus Trametinib - Findings from the COMBI-AD study
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...
Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...
Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results
The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...
ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...
The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
The U.S. Food and Drug Administration ( FDA ) has approved Gallium 68 PSMA-11 ( Ga 68 PSMA-11 ), the...
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...